Sun Pharmaceutical Industries has acquired three brands from Aksigen Hospital Care, including Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg, and Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg, and Rutoside Trihydrate 100 mg), and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg, and Rutoside Trihydrate 100 mg). The Drugs Controller General of India (DCGI) has approved all of the brands for post-operative inflammation in patients undergoing minor surgery and dental procedures.
Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain, and Rutoside (TBR) to complete and receive DCGI approval in India. Aksigen registered and launched the brands in India in 2013. “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio,” Sun Pharma said. This systemic enzyme therapy combination is used to control edoema and accelerate healing. In a comparative clinical trial in India, the brands significantly improved post-operative pain and inflammation control and resolution.” In India, the total market for proteolytic enzymes for healing, pain, and edoema is estimated to be around Rs 500 crore (as per IQVIA data MAT Nov 2022).